FIELD: chemistry; pharmaceutics.
SUBSTANCE: invention relates to crystalline forms of 4-[9-(tetrahydrofuran-3-yl)-8-(2,4,6-trifluorophenylamino)-9H-purin-2-ylamino]cyclohexan-1-ol of formula 
, which have kinase inhibiting properties and can be used to treat or prevent: (a) cancer; (b) an inflammatory condition or (c) an immunologic condition. The invention particularly relates to a crystalline form A, having an X-ray powder diffraction pattern with peaks at about 12.4, 16.0 and 18.5°2θ and further has peaks at about 17.7, 23.2 and 24.1°2θ; a hydrate crystalline form A, having an X-ray powder diffraction pattern with peaks at about 6.5, 13.0 and 23.0°2θ and further has peaks at about 13.4, 20.1 and 23.8°2θ; a crystalline form of a hydrochloride salt A, having an X-ray powder diffraction pattern with peaks at about 17.3, 18.7 and 22.4°2θ, and contains about two mole equivalents of chloride ions.
EFFECT: invention relates to methods of producing a crystalline form A, a pharmaceutical composition containing said crystalline forms and a treatment method.
15 cl, 16 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR KINASE CASCADE MODULATION AND METHODS OF THEIR APPLICATION | 2010 |
|
RU2569299C2 |
| CRYSTALLINE FORMS OF LTA4H INHIBITOR | 2019 |
|
RU2808992C2 |
| SALTS AND POLYMORPHS OF SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE | 2015 |
|
RU2732125C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| SOLID FORMS OF THE COMPOUND MODULATING THE KINASES | 2016 |
|
RU2730506C2 |
| METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES | 2012 |
|
RU2626883C2 |
| SOLID FORMS OF 2-(5-(4-(2-MORPHOLINOETHOXY)PHENYL)PYRIDINE-2-IL)-N-BENZYLACETAMIDE | 2018 |
|
RU2802964C2 |
| SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USE | 2012 |
|
RU2611007C2 |
| NEW CRYSTALLINE SALT FORM OF 2,2-DIMETHYL-6-((4-((3,4,5-TRIMETHOXYPHENYL)AMINO)-1,3,5-TRIAZIN-2-YL)AMINO)-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE FOR MEDICAL USE | 2016 |
|
RU2621187C1 |
| PHARMACEUTICAL COMPOUNDS | 2005 |
|
RU2416610C2 |
